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Seeking new biomarkers for epithelial ovarian cancer, the fifth most common cause of death from all cancers in women and the
leading cause of death fromgynaecologicalmalignancies, we performed ameta-analysis of three independent studies and compared
the results in regard to clinicopathological parameters.This analysis revealed thatGAS6was highly expressed in ovarian cancer and
therefore was selected as our candidate of choice. GAS6 encodes a secreted protein involved in physiological processes including
cell proliferation, chemotaxis, and cell survival.We performed immunohistochemistry on various ovarian cancer tissues and found
that GAS6 expression was elevated in tumour tissue samples compared to healthy control samples (𝑃 < 0.0001). In addition, GAS6
expression was also higher in tumours from patients with residual disease compared to those without. Our data propose GAS6 as
an independent predictor of poor survival, suggesting GAS6, both on the mRNA and on the protein level, as a potential biomarker
for ovarian cancer. In clinical practice, the staining of a tumour biopsy for GAS6 may be useful to assess cancer prognosis and/or
to monitor disease progression.
1. Introduction
Epithelial ovarian cancer (EOC) is the fifth most common
cause of death from all cancers in women and the lead-
ing cause of death from gynecological malignancies [1, 2].
Most patients (70%) present at initial diagnosis with locally
advanced or disseminated disease, which is characterized by
invasion of surrounding organs and in high stage cases of the
peritoneal cavity.The survival rate of womenwithwidespread
metastatic disease is a dismal 10–20% [3]. This poor overall
prognosis is due to the lack of screening tools for early stage
disease, the nonspecific nature of symptoms, and drug resis-
tance in advanced disease. A major challenge is the identifi-
cation of new tumour markers. These will improve diagnosis
and may serve as prognostic indicators and targets for new
therapeutic strategies [4].
Cancer biomarkers can exist in various forms among oth-
ers as DNA (genome), mRNA (transcriptome), cell surface or
secreted proteins (proteome), and carbohydrates (glycome).
Transcriptomic microarrays provide a broad picture of gene
expression by monitoring the intensity expression levels of
thousands of genes simultaneously, which together provide a
molecular blueprint of the tumours, or what is defined as an
expression profile [5]. The use of transcriptomic-based high-
throughput platforms is therefore a good starting point for
the identification of cancer-relevant biomolecules. However,
most studies are based on a single patient cohort and often
have small sample size. Meta-analysis of transcriptomic data
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from several independent studies is a powerful approach
to detect biomarkers with much greater sensitivity and,
potentially, specificity.
In order to identify biomarkers for ovarian cancer based
on survival, we performed a meta-analysis of independent
studies based on individual observations [6–9]. From this
analysis GAS6 emerged as our candidate of choice. GAS6 is
overexpressed in various cancers including ovarian cancer
[10–12]. Its encoded product GAS6 is a secreted protein
involved in a broad range of physiological processes including
the induction of cell proliferation, chemotaxis, and survival
[13–15]. To the best of our knowledge, there has only been
one other study that investigated GAS6 expression in ovarian
cancer [16]. The authors observed that GAS6 and its encoded
protein were overexpressed in ovarian cancers; however, the
relationship between GAS6 expression in levels and various
clinicopathological parameters was not reported. In our
study with a large cohort of healthy controls and adenocarci-
noma patients, immunohistochemistry for GAS6 expression
in epithelial ovarian cancer samples confirmed the findings
of our meta-analysis; comparison of the data with various
clinicopathological parameters identified GAS6 as an inde-
pendent predictor of poor prognosis.
2. Materials and Methods
2.1. Meta-Analysis. Combining raw data from microarray
studies on different platforms remains problematic due to
data that are not commensurable. Meta-analysis of test statis-
tics fromdifferent studies provides a powerful and robust way
to integrate heterogeneousmicroarray studies.We carried out
ameta-analysis of initially four similarly designedmicroarray
studies of ovarian cancer [6–9]. After the retraction of the
Dressman paper [9] in February 2012, we recalculated the
meta-analysis of the three remaining studies.
We used the analysis strategy outlined in Wirapati et al.
[16]. Beginningwith the complete preprocessed primary data,
probes were matched to UniGene identifiers. We considered
the union of all genes that are represented in at least one
study. For each gene, we computed a normally distributed test
statistic measuring the association of expression with pres-
ence of ovarian cancer (probit-transformed 𝑡-statistic). We
thenmeta-analytically combined these single gene individual
study 𝑧-scores𝑍
𝑖𝑘
across studies using equal weighting by the
inverse normal method [17]:
𝑍
𝑖
=
𝐾𝑖
∑
𝑘=1
𝑍
𝑖𝑘
√𝐾
𝑖
, (1)
where 𝑖 indicates gene, 𝑘 indicates study, and 𝐾
𝑖
is the
number of datasets where gene 𝑖 is present (i.e., any platform
missing the gene is ignored). The resulting 𝑍
𝑖
should all
be (approximately) distributed as standard normal and are
ranked according to size (or, equivalently, by 𝑃 value).
2.2. Clinicopathological Patient Cohort. Two patient cohorts
from the University Hospital Zurich and Spital Limmattal
were chosen for this study: (a) prospectively included patients
prior to surgery for unknown pelvic mass after giving
informed consent in accordance with ethical regulations
(SPUK, Canton of Zurich, Switzerland; StVNr. 06/2006), and
(b) ovarian tumour patients diagnosed since 1991 which were
retrospectively included after receiving ethical allowance.
Patients with a history of cancer or autoimmune diseases
were excluded. The cohort consisted of 800 patients and was
composed of three major patient groups: (1) healthy patients
with normal ovaries and tubes; (2) benign tumours or border-
line tumours of the ovaries; (3) epithelial ovarian, tubal, or
peritoneal cancers. All clinicopathological patient data such
as FIGOstage, grade, residual disease, presence of ascites, past
and present medical illness, ultrasonic findings and outcome
data were stored in a specially designed in-house database
(PEROV) based on ACCESS (Microsoft, USA). Histopathol-
ogy of all study patients was independently re-evaluated by a
pathologist specialized in the field of gynaecological oncology
(R.C.), and patients with unclear or mixed diagnoses were
excluded from the study. Tissue microarrays were con-
structed using a Tissue Microarrayer (Beecher Instruments,
USA). Each patient was represented by two cores (1.0 or
2.0mm) from different regions of the tumour.
2.3. Immunohistochemistry. For the detection of GAS6, tissue
microarray slides were stained using the Ventana Benchmark
automated staining system (VentanaMedical Systems, USA).
For antigen retrieval, slides were incubated with Tris-based
buffer (with slightly alkaline pH) for 1 hour, according to stan-
dard procedures. Slides were incubated with the anti-human
GAS6 (R&D Systems, USA) for 1 hour. Negative controls
involved the omission of the primary antibody. Counterstain-
ing was performed with hematoxylin and 1% acid alcohol.
To assess GAS6 expression level, a weighted average (WA)
methodof scoringwas performed. First, each core samplewas
scored for overall percentage (between 0 and 100) and overall
intensity (0 to 3).The overall percentage and overall intensity
of each sample were then multiplied, with the resultant num-
ber for each sample core within the same cohort summed,
and divided by the total number of cores. Scoring was inde-
pendently assessed by a researcher (M.B.) and a pathologist
(R.C.), and discrepancies were resolved by consensus.
2.4. Cell Lines and Tissue Culture. The human ovarian cancer
cell lines IGROV1, SKOV3, OVCAR3, and A2780 (all serous)
were maintained in RPMImedia, and TOV112D (endometri-
oid) and TOV21G (clear cell) cell lines were cultured in
DMEMmedia.Thehumanovarian surface epithelial cell lines
HOSE6.3 and HOSE17.1 were cultured in a 50 : 50 mix of
Media 199 andMCDB 105media. All culturemedia were sup-
plemented with 10% foetal bovine serum, 2mML-glutamine,
and penicillin/streptomycin. Cells were incubated at 37∘C in
a humidified atmosphere of 5% CO
2
/air.
2.5. Western Blot. Subconfluent cells were washed thrice in
PBS, then scraped offflasks inRIPAbuffer (150mmol/LNaCl,
1% Triton X-100, 0.1% SDS, and 25mmol/L Tris-Cl (pH 7.5)),
and supplemented with protease inhibitor cocktail tablets
(Roche Diagnostics, Germany). The cells were snap-frozen
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Table 1: Clinicopathological data for nonmucinous EOC cohort
(𝑛 = 172).
Variable Number %
Age at diagnosis
>60 97 56.4
<60 73 43.6
FIGO stage
I 32 18.6
II 17 9.9
III 72 41.9
IV 43 25.0
NA 8 4.6
TNM-T
1 32 18.6
2 21 12.2
3 107 62.2
4 7 4.1
NA 5 2.9
TNM-N
0 96 55.8
1 41 23.8
NA 35 20.4
TNM-M
0 101 58.7
1 45 26.2
NA 26 15.1
Grade
1 15 8.7
2 58 33.7
3 98 57.0
NA 1 0.6
Histological type
Serous (SOC) 84 48.8
Endometrioid (EnOC) 39 22.7
Clear cell (ClCOC) 42 24.4
Transitional cell (TCOC) 7 4.1
Ascites at primary diagnosis
Yes 89 51.7
No 83 48.3
Residual disease
≥10mm 84 48.8
≤10mm 49 28.5
NA 32 22.7
Primary cancer origin
Both ovaries 80 46.5
Left ovary 43 25.0
Right ovary 40 23.2
NA 9 5.3
Performance status
Healthy 77 44.8
Table 1: Continued.
Variable Number %
Systematic disease 55 31.9
Severely sick 1 0.6
NA 39 22.7
With cancer family history CA125 (preoperative)
Yes 40 23.3
≥35U/mL 75 43.6
≤35U/mL 10 5.8
NA 87 50.6
Relapse
Yes 140 81.4
No 32 18.6
Platinum chemotherapy
Sensitive 45 26.2
Resistant 93 54.0
NA 34 19.8
Outcome
Death related to malignancy 88 51.2
Unrelated, no disease 1 0.6
NA 83 48.2
Progressive disease (months)
Yes 36 20.9
No 136 79.1
in liquid nitrogen, thawed, and then centrifuged at 13,000 g
for 10mins.The supernatant (whole cell lysate)was quantified
using the BCA protein estimation reagent (Thermoscientific,
USA). Twentymicrograms of lysate wasmixedwithNuPAGE
loading dye and reducing agents (Invitrogen) then heated at
95∘C for 5mins before loading onto sodium dodecyl sulphate
(SDS)-polyacrylamide gels (Invitrogen). All gels were trans-
ferred to PVDF membranes and blocked for 1 hour at
PBS containing 0.1% Tween 20 (PBS/T20). Membranes were
incubatedwith the primary antibodies forGAS6 (anti-human
GAS6; R&D Systems, USA) and GAPDH (anti-human
GAPDH; Santa Cruz, USA) in PBS/T20 overnight at 4∘C,
washed thrice with PBS/T20, and incubated with secondary
antibodies conjugated to horse radish peroxidase (rabbit anti-
goat IgG-HRP; Santa Cruz, USA). Membranes were washed
again in PBS/T20, incubated with ECL (Elmer Perkins,
Australia), and then developed on photo film (Sigma, USA).
Quantification of signal intensities was performed using
Bio-Rad GS-800 densitometer with Quantity One software
(Hercules, USA).
2.6. Statistical Analysis. Immunohistochemical scoring as
assessed by intensity and percentage of stained cells was
combined in a weighted average score, which takes in
account both values and the number of cores available
per patient: ((percentage 1 × intensity 1) × (percentage 𝑛 ×
intensity 𝑛)/number of cores). Box plots were created for
weighted average values depending on the clinicopathologi-
cal diagnosis. To see whether there is a difference in means
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Table 2: Top 34 overexpressed genes obtained by meta-analysis.
Gene SD Comb. 𝑍
R3HDM1 0.3 3.45
ATR 0.3 3.23
UVRAG 0.3 3.16
TARBP1 0.31 3.01
PCNA 0.39 3.09
ZNF184 0.44 3.26
DSC2 0.45 3.75
CDH6 0.55 3.17
NUP205 0.59 3.07
NEK2 0.63 3.05
EYA2 0.71 3.78
E2F3 0.72 3.17
SOX9 0.75 3.56
PEA15 0.86 3.82
SPOCK2 0.88 3.5
BTG3 0.89 3.25
FDPS 0.93 3.68
GAS6 0.95 3.10
DDR1 0.96 3.93
HLTF 0.97 3.08
PRDX6 0.98 3.05
IGFBP2 1.07 3.48
CELSR2 1.13 3.1
ASNS 1.17 3.49
SMG7 1.25 3.46
CD47 1.29 3.89
CXADR 1.3 5.64
CRIP2 1.3 3.74
GUK1 1.38 3.81
BMI1 1.5 3.37
MEIS1 1.64 4.45
WFDC2 1.66 5.88
RBM38 1.91 3.18
SCNN1A 1.94 3.77
between those groups, an analysis of variance (ANOVA)
was performed. All western blot experiments have been
performed as triplicates (B.T.). Comparison of two data values
was measured for their significance using Mann-Whitney 𝑈
tests; in relation to multiple values, the Kruskall-Wallis test
was applied (a nonparametric method for testing differences
in median between several groups). Correlations of clinico-
pathological data with outcome parameters were performed
using the Kaplan-Meier analysis (univariate analysis) and
multivariate using Cox proportional hazard models. Meta-
analysis and all statistical analyses have been performed by
two expert mathematicians specialising in the analyses of
bioinformatics high-throughput data analysis (D.G., A.L.).
All data analysis except the meta-analysis were performed
using the open source statistical programming language R
(http://CRAN.R-project.org/, version 2,8.1). A 𝑃 value of
<0.05 was considered as statistically significant.
3. Results
3.1. Characteristics of Patient Cohort. Our cohort consisted of
a variety of tissues: epithelial ovarian cancers (𝑛 = 172), ovar-
ian borderline (𝑛 = 40), cystic adenoma (𝑛 = 2), normal fal-
lopian tubes (𝑛 = 3), and ovarian surface epithelium (𝑛 = 6).
In the cancer cohort of 172, 18.6% were of FIGO stage I, 9.9%
of stage II, 41.9% of stage III, and 25% of stage IV. The pre-
dominant histotype was serous (48.8%), followed by clear cell
(24.4%), then endometrioid (22.7%), and transitional (4.1%).
Fifty-six percent of womenwere over the age of 60, compared
to 43.6% under 60. Other clinicopathological parameters
accessible within our cohort included TNM-T, TMN-N, and
TMN-M scores, grade, the presence of ascites at initial
diagnosis, primary cancer origin, overall health, preoperative
CA125 levels, relapse, sensitivity to platinum chemotherapy,
and progressive disease (Table 1).
3.2. Meta-Analysis of DNA Microarray from Four Publica-
tions Identifies GAS6 as a Highly Ranked Robust Candidate
Biomarker for Ovarian Cancer. Although no single study
shows GAS6 to rank particularly high, meta-analysis identi-
fies GAS6 as an interesting potential biomarker. GAS6 ranks
in the middle of the top candidates (combined 𝑧 = 3.10, nom-
inal 𝑃 value < 0.001) when considering both DS and 𝑧-scores
genes. Several other highly ranked genes have achieved their
rank based on one outlier 𝑧-score. However, the GAS6 result
is robust when considering not only the combined 𝑧-score
in isolation but also the variability of the individual 𝑧-scores.
This is shown in Table 2 as well as in a reproducibility plot
(data not shown) incorporating both the standard deviation
(SD) and the combined 𝑧-score of all 4 transcriptomic data
sets. The highly upregulated ovarian cancer genes from this
meta-analysis are listed in Table 2 in the order of increasing
SD (decreasing reproducibility). Hereby, GAS6 is roughly in
the middle of this top candidate group, where also well-
known ovarian cancer markers like HE4 (WFDC2) or DDR1
are listed. Moreover, 50% (17/34) of these top candidates have
been linked to ovarian cancer in the scientific literature.These
data suggest a high degree of consistency across the diverse
studies and confirming its suitability as a biomarker.
3.3. GAS6 Is Overexpressed in Ovarian Cancers. With our
meta-analysis of transcriptomic data revealing that GAS6
mRNA is highly expressed in ovarian cancer, we assessed the
expression of GAS6 in various ovarian tissues by immuno-
histochemistry. Strong cytoplasmic staining of GAS6 was
observed in epithelial ovarian cancer tissues. Based on the
weighted average (WA) method of scoring, GAS6 expression
was stronger in epithelial ovarian cancers (EOC; 𝑛 = 172) and
ovarian borderline tumours (OBL; 𝑛 = 40) than in ovarian
surface epithelium (OSE; 𝑛 = 6) or normal fallopian tubes
(Tube; 𝑛 = 3) (𝑃 = 4.97 × 10−5) (Figure 1(a)). This trend
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Figure 1: GAS6 is overexpressed in ovarian cancers. (a) Box plot demonstrating GAS6 weighted average expression scores on various ovarian
tissues as assessed by immunohistochemistry. Statistical test performed was the Kruskal-Wallis test. OSE: ovarian surface epithelium; CystA:
cystadenoma; OBL: ovarian borderline tumour; EOC: epithelial ovarian cancer. (b) Western blots for GAS6 on a panel of ovarian cell lines.
Left panel shows original blot, right panel shows relative expression based on densitometric analysis (density of GAS6 divided by density of
GAPDH). Results from a representative experiment are shown. Normal cell lines (HOSE6.3 andHOSE17.1) aremarked (framed or black bars).
of greater expression in tumour than in normal tissue was
confirmed by western blot on whole cell lysates of a panel
of human ovarian cell lines where, apart from the OVCAR3
cell line, all the ovarian carcinoma cell lines IGROV1, SKOV3,
A2780 (all serous), and the TOV112D (endometrioid) and
the TOV21G (clear cell) cell lines displayed elevated GAS6
expression compared to the two human ovarian epithelial
cell lines (nontumour origin) HOSE6.3 and HOSE17.1 (Fig-
ure 1(b)).
3.4. GAS6 Expression Is Elevated in Ovarian Cancers from
Patients with Residual Disease. Within the cancer cohort
(Table 1), GAS6 expression is significantly higher in tumours
from patients with residual disease (defined as those with
observable lesions greater than 10mm in size) than those
without (𝑃 = 0.0156) (Figure 2(a)). Similarly, under the
TNM-M scoring system, tumours from T4 patients (𝑛 = 7)
tendedto have higher GAS6 expression compared to T1 (𝑛 =
32),T2 (𝑛 = 21), and T3 (𝑛 = 107) patients (patients with
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Figure 2: GAS6 expression level in relation to various clinicopathological parameters. (a) Ovarian cancers from patients with residual
disease have significantly higher level of GAS6 expression. (b) Ovarian cancers from TMN T4 patients tended to have higher expression
of GAS6. (c) GAS6 expression was similar across clear cell, endometrioid, serous, and transitional cell ovarian cancers as assessed by
immunohistochemistry on tissue microarray. CICOC: clear cell ovarian cancer; EnOC: endometrioid ovarian cancer; SOC: serous ovarian
cancer; TCOC: transitional cell ovarian cancer.
smaller tumours) (𝑃 = 0.07163) (Figure 2(b)). The expres-
sion level of GAS6 was not different across all histotypes
investigated (Figure 2(c)). Similar observations were found
with other clinicopathological parameters such as tumour
stage, grade, presence of ascites at initial diagnosis, TMN-N
(lymph node involvement) and TNM-M (metastases) status,
and relapse status (data not shown).
3.5. GAS6 Expression Is an Independent Predictor of Earlier
Death. To find associations between GAS6 expression levels
and patient survival, univariate Cox proportional hazard
models were constructed. High tumour expression of GAS6
(WA > 2) was associated with significantly shorter disease-
free survival (𝑃 = 0.0004) (Figure 3). By multivariate analysis
(proportional hazards model), GAS6 expression was still an
independent negative prognostic factor (𝑃 = 0.0028, likeli-
hood ratio). As expected, patients with earlier stage (FIGO
I/II), grade 1, no residual disease, TMN-M 0, and TMN T2
disease had significantly longer DFS than their counterparts
(Figure 3). In terms of relapse-free survival, high GAS6
expression level had no effect (𝑃 = 0.2878) (data not shown).
Again as expected, other clinicopathological parameters
yielded significant 𝑃 values (data not shown).
4. Discussion
Transcriptomic analysis of the cancer samples is frequently
performed, often being a good starting point for the identifi-
cation of novel biomarkers for a given cancer type. However,
most transcriptomic studies to date have been performed on
a single cohort and are often limited in sample size. Meta-
analysis of combined transcriptomic microarray datasets is
a powerful method to greatly increase the sensitivity in
revealing biomarkers for disease and, potentially, with greater
specificity. In order to identify new biomarkers for ovar-
ian cancer based on survival, we performed meta-analysis
of individual observations initially from four independent
studies [6–9] and then after the retraction of the study by
Dressman et al. [9] in 2012 from three independent studies.
These analyses revealed GAS6 as our candidate of choice.
In our study, we found that GAS6 is overexpressed
in ovarian cancer and therefore confirmed the findings of
Sun et al. [12]. More importantly, however, we demonstrate
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Variable Coeff. SE Exp. (coeff.) Exp. (−coeff.) (logrank) likelihood ratio
WA >2 1.0563 0.3125 2.8756 0.3478 0.0028
Stage (I/II) 0.3554
0.1548 6.46
Grade 1 0.5880 0.2428 4.118 0.009 0.0023
Residual disease 0.3812 0.099 10.02
Ascites 0 0.0150 0.2066 1.015 0.9815 0.9421 0.9421
TNM-N 0 0.2669 0.7944 1.259 0.3874 0.396
TNM-M 0.2365
0.3831
2.610
TNM-T2 0.3252 0.1749 5.718
−1.8656
−1.4154
−2.3000
−0.2302
−0.9595
−1.7436
4 × 10
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2 × 10
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3 × 10
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[0.007713 : 0.3107]
[0.07671 : 0.7687]
[0.0473 : 0.2108]
[0.6771 : 1.522]
[0.4709 : 1.340]
[0.241 : 0.609]
[0.09246 : 0.3309]
[1.559 : 5.306]
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Figure 3: High expression of GAS6 correlates with shorter disease-free survival.TheKaplan-Meier curves of ovarian cancer patients stratified
to high or low GAS6 expression (cutoff: WA of 2). Multivariate survival analysis indicates that high expression of GAS6 is an independent
negative prognostic marker (𝑃 = 0.0028, likelihood ratio test).
that GAS6 is an independent predictor of earlier death. In
addition, GAS6 expression level is higher in patients with
greater tumour burden and/or with residual disease. These
results suggest that both GAS6 transcript and protein may
serve as biomarkers for ovarian cancer. In clinical practice,
the staining of a tumour biopsy for GAS6 may be useful for
cancer prognosis assessment and/or for disease progression
monitoring.
Although the prognostic and diagnostic utility of bio-
markers is important, the understanding of its pathophysi-
ological role is also necessary as this knowledge may help
in the design of a novel targeted therapy for the cancer.
However, functional studies of GAS6 in ovarian cancer were
beyond the scope of our study, but earlier studies have shown
that GAS6 is a member of the vitamin K-dependent protein
family [18]. It is structurally comprised of an N-terminal
𝛾-carboxyglutamic (Gla) domain, four epidermal growth
factor- (EGF-) like sequences, and a C-terminal composed
of two globular laminin G-like (LG) domains [19]. GAS6 is
a ligand for receptor tyrosine kinases (RTKs) of the TAM
family: Tyro3, AXL, andMerTK, with binding affinities in the
order of AXL > Sky > Mer [20]. The role of the GAS6/AXL
axis in cancer is well documented. GAS6 is overexpressed
in glioblastoma [10], gastric [11], and ovarian [12] cancers.
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Likewise, AXL is overexpressed in colon [21], thyroid [22],
breast [23], renal cell [24], and ovarian [25] cancers. The
latter study suggests that the GAS6/AXL axismay be involved
in driving tumorigenesis of this cancer [25]. AXL protein
expression was found to be significantly higher in ovarian
carcinomas than in ovarian epithelium, and knockdown of
AXL in SKOV3 cells also reduced the expression of MMP-
1 and MMP-9, which contribute to tumour cell invasion.
AXL knockdown also inhibited the size and the number
of metastases in a xenogeneic mouse model of ovarian
cancer metastasis.These experimental data together with our
results that GAS6 overexpression is associated with shorter
survival suggest that interventions which inhibit this pathway
could have therapeutic potential. Since GAS6 is a secreted
protein, a rational therapeutic approach is the development
of an antibody against it. By reducing the amount of free
GAS6 in serum and/or ascites, the direct growth-promoting
effects of the GAS6/AXL may be transiently reduced. For
this reason, an anti-GAS6 antibody may be employed as
a useful adjunct therapy for ovarian cancer. There is also
evidence in other cancer types that GAS6 may be involved
in resistance to chemotherapy. It was shown that treatment
of AXL-transfected U937 acute myeloid leukaemia cells with
recombinant GAS6 resulted in resistance to doxorubicin,
VP16, and cisplatin, an effect associated with increased
expression of the antiapoptotic molecules Bcl-2 and Twist
[26]. If the GAS6/AXL axis is also involved in chemoresis-
tance in ovarian cancer, targeting this pathway may sensitise
tumours to paclitaxel and carboplatin, the current mainstays
of therapy, whilst also directly inhibiting tumour growth.
Such studies are definitely warranted.
Although the majority of studies have shown that the
GAS6/AXL axis helps drive tumorigenesis, there have been
reports that suggest the contrary, which again highlights
the notion that the function of GAS6 is highly context
dependent. GAS6was also shown to dose dependently inhibit
the proliferation of the prostate cancer cell lines PC3 and
DU145 [27], but the opposite effect was reported on the
same cell lines by another group [28]. In a cohort of breast
cancer patients, GAS6 expression positively correlated with
favourable prognostic variables such as lymph node nega-
tivity, smaller tumour size, and low Nottingham prognostic
index score [29]. Therefore, from a therapeutic point of view,
more robust studies on the function of GAS6 in ovarian
cancer are required.
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